An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci
Human papillomavirus type 16 (HPV-16) is the major causative agent of cervical cancer. To date, vaccine strategies against HPV-16 are based on the ability of the E7 oncoprotein to elicit an immune response against this virus. In this study, the use of an inducible or a constitutive system to produce the HPV-16 E7 protein in Lactococcus lactis, a non-pathogenic and non-invasive Gram-positive bacterium, was compared. The highest E7 production was obtained with the inducible system. When mice were immunized intranasally with recombinant lactococci expressing either inducible or constitutive E7, an antigen-specific cellular response (i.e. secretion of IL2 and IFN-γ cytokines) was evoked and was substantially higher in mice receiving L. lactis expressing E7 with the inducible system. As bacterial antigen location may influence the immune response, recombinant L. lactis strains that produced E7 in three cellular locations, intracellular, secreted or cell-wall-anchored were evaluated. The highest immune response was elicited by administration of L. lactis producing an inducible cell-wall-anchored form of E7 protein. These promising results represent a step towards the development of a new, safe mucosal vector to treat HPV-related cervical cancer.
BakerC. C.,
PhelpsW. C.,
LindgrenV.,
BraunM. J.,
GondaM. A.,
HowleyP. M.1987; Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 61:962–971
BedellM. A.,
JonesK. H.,
LaiminsL. A.1987; The E6-E7 region of human papillomavirus type 18 is sufficient for transformation of NIH 3T3 and rat-1 cells. J Virol 61:3635–3640
Bermúdez-HumaránL. G.,
LangellaP.,
MiyoshiA.,
GrussA.,
Taméz-GuerraR.,
Montes de Oca-LunaR.,
Le LoirY.2002; Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol 68:917–922[CrossRef]
Bermúdez-HumaránL. G.,
Cortes-PerezN. G.,
Le LoirY.,
GrussA.,
Rodríguez-PadillaC.,
Saucedo-CardenasO.,
LangellaP.,
Montes de Oca-LunaR.2003a; Fusion to a carrier protein and a synthetic propeptide enhances E7 HPV-16 production and secretion in Lactococcus lactis. Biotechnol Prog 19:1101–1104[CrossRef]
Bermúdez-HumaránL. G.,
LangellaP.,
CommissaireJ.,
GilbertS.,
Le LoirY.,
L'HaridonR.,
CorthierG.2003c; Controlled intra- or extracellular production of staphylococcal nuclease and ovine omega interferon in Lactococcus lactis
. FEMS Microbiol Lett 224:307–313[CrossRef]
ChatelJ. M.,
LangellaP.,
Adel-PatientK.,
CommissaireJ.,
WalJ. M.,
CorthierG.2001; Induction of mucosal immune response after intranasal or oral inoculation of mice with Lactococcus lactis producing bovine beta-lactoglobulin. Clin Diagn Lab Immunol 8:545–551
Cortes-PerezN. G.,
Bermúdez-HumaránL. G.,
Le LoirY.,
Rodríguez-PadillaC.,
GrussA.,
Saucedo-CardenasO.,
LangellaP.,
Montes de Oca-LunaR.2003; Mice immunization with recombinant lactococci displaying a surface HPV-16 E7 oncoprotein. FEMS Microbiol Lett 229:37–42[CrossRef]
de RuyterP. G.,
KuipersO. P.,
de VosW. M.1996; Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl Environ Microbiol 62:3662–3667
DrouaultS.,
CorthierG.,
EhrlichS. D.,
RenaultP.1999; Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl Environ Microbiol 65:4881–4886
DysonN.,
HowleyP. M.,
MungerK.,
HarlowE.1989; The human papillomavirus-16 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934–937[CrossRef]
EnoufV.,
LangellaP.,
CommissaireJ.,
CohenJ.,
CorthierG.2001; Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl Environ Microbiol 67:1423–1428[CrossRef]
GassonM. J.1983; Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol 154:1–9
GeoffroyM. C.,
GuyardC.,
QuatannensB.,
PavanS.,
LangeM.,
MercenierA.2000; Use of green fluorescent protein to tag lactic acid bacterium strains under development as live vaccine vectors. Appl Environ Microbiol 66:383–391[CrossRef]
GérardC. M.,
BaudsonN.,
KraemerK.,
BruckC.,
GarconN.,
PatersonY.,
PanZ. K.,
PardollD.2001; Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 19:2583–2589[CrossRef]
JabbarI. A.,
FernandoG. J.,
SaundersN.,
AldoviniA.,
YoungR.,
MalcolmK.,
FrazerI. H.2000; Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 18:2444–2453[CrossRef]
KokJ.,
van der VossenJ. M.,
VenemaG.1984; Construction of plasmid cloning vectors for lactic streptococci which also replicate in Bacillus subtilis and Escherichia coli
. Appl Environ Microbiol 48:726–731
KoutskyL. A.,
AultK. A.,
WheelerC. M.,
BrownD. R.,
BarrE.,
AlvarezF. B.,
ChiacchieriniL. M.,
JansenK. U.2002; A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645–1651[CrossRef]
KuipersO. P.,
de RuyterP. G.,
KleerebezenM.,
de VosW. M.1998; Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol 64:15–21[CrossRef]
LangellaP.,
Le LoirY.,
EhrlichS. D.,
GrussA.1993; Efficient plasmid mobilization by pIP501 in Lactococcus lactis subsp. lactis
. J Bacteriol 175:5806–5813
LondoñoL. P.,
ChatfieldS.,
TindleR. W.,
HerdK.,
GaoX. M.,
FrazerI.,
DouganG.1996; Immunization of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen. Vaccine 14:545–552[CrossRef]
NortonP. M.,
BrownH. W.,
WellsJ. M.,
MacphersonA. M.,
WilsonP. W.,
Le PageR. W.1996; Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis
. FEMS Immunol Med Microbiol 14:167–177[CrossRef]
PiardJ. C.,
Jimenez-DiazR.,
FischettiV. A.,
EhrlichS. D.,
GrussA.1997; The M6 protein of Streptococcus pyogenes and its potential as a tool to anchor biologically active molecules at the surface of lactic acid bacteria. Adv Exp Med Biol 418:545–550
ReinsteinE.,
ScheffnerM.,
OrenM.,
CiechanoverA.,
SchwartzA.2000; Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 19:5944–5950[CrossRef]
ReveneauN.,
GeoffroyM. C.,
LochtC.,
ChagnaudP.,
MercenierA.2002; Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations. Vaccine 20:1769–1777[CrossRef]
RibeiroL. A.,
AzevedoV.,
Le LoirY.,
OliveiraS. C.,
DieyeY.,
PiardJ. C.,
GrussA.,
LangellaP.2002; Efficient production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis : a first step towards food-grade live vaccines against brucellosis. Appl Environ Microbiol 68:910–916[CrossRef]
RobinsonK.,
ChamberlainL. M.,
SchofieldK. M.,
WellsJ. M.,
Le PageR. W.1997; Oral vaccination of mice against tetanus with recombinant Lactococcus lactis
. Nat Biotechnol 15:653–657[CrossRef]
SteidlerL.,
RobinsonK.,
ChamberlainL.,
SchofieldM.,
RemautE.,
Le PageR. W. F.,
WellsJ. M.1998; Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun 66:3183–3189
van der VossenJ. M.,
van der LelieD.,
VenemaG.1987; Isolation and characterization of Streptococcus cremoris Wg2-specific promoters. Appl Environ Microbiol 53:2452–2457
An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci